insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

APTO · Aptose Biosciences Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$3.62M-$2.21M$3.30M$2.36M-$4.70M$4.41M$6.45M-
SG&A$3.56M-$2.71M$3.62M$3.10M-$2.26M$2.93M$3.31M-
Total Operating Expenses$7.18M-$4.91M$6.92M$5.46M-$6.96M$7.34M$9.76M-
D&A$2.0K---$16.0K-$4.0K$8.0K$16.0K-
Operating Income----------
Interest Expense----------
Income Tax----------
Net Income($7.63M)-($5.12M)($7.04M)($5.54M)-($6.95M)($7.25M)($9.64M)-
EPS - Basic($2.99)-($2.01)($2.76)($2.61)-($0.37)($0.43)($0.73)-
EPS - Diluted($2.99)-($2.01)($2.76)($2.61)-($0.37)($0.43)($0.73)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$1.02M$935.0K$613.0K$553.0K$4.74M$6.15M$7.96M$8.33M$7.35M$9.25M
Accounts Receivable----------
Inventory----------
Accounts Payable$3.81M$2.91M$1.46M$2.88M$2.39M$1.26M$1.83M$7.11M$2.42M$3.49M
Current Assets$6.16M$6.45M$3.78M$3.27M$6.97M$9.53M$10.23M$10.16M$11.82M$11.89M
Total Assets$10.72M$10.01M$6.34M$5.59M$7.47M$10.13M$10.93M$10.95M$12.80M$12.99M
Current Liabilities$11.24M$9.31M$7.08M$9.00M$6.32M$4.46M$9.76M$12.71M$12.14M$15.27M
Long-term Debt----------
Total Liabilities$45.40M$37.18M$25.79M$19.96M$14.86M$14.67M$20.06M$13.13M$12.66M$15.89M
Stockholders' Equity($34.67M)($27.17M)($19.45M)($14.37M)($7.39M)($4.54M)($9.13M)($2.18M)$137.0K($2.90M)
Retained Earnings($574.07M)($566.43M)($558.68M)($553.55M)($546.51M)($540.97M)($539.38M)($532.43M)($525.18M)($515.54M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($5.84M)---($2.79M)-($10.38M)($5.78M)($11.76M)-
Investing Cash Flow$0---$0-$0$2.01M($1.99M)-
Financing Cash Flow$5.85M---$829.0K-$10.01M$4.75M$11.85M-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-71.2%--80.8%-126.0%-74.2%--63.6%-66.2%-75.3%-
Return on equity22.0%-26.3%49.0%75.0%-76.1%333.3%-7036.5%-
Return on invested capital----------
Liquidity
Current ratio0.550.690.530.361.102.141.050.800.970.78
Quick ratio0.550.690.530.361.102.141.050.800.970.78
Cash ratio0.090.100.090.060.751.380.820.660.610.61
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier-0.31-0.37-0.33-0.39-1.01-2.23-1.20-5.0393.40-4.48
Liabilities / Assets4.233.714.073.571.991.451.841.200.991.22
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)----------
Net income growth (YoY)-37.7%-26.3%2.9%42.5%-39.3%48.7%29.5%-
EPS growth (YoY)-14.6%--443.2%-541.9%-257.5%-79.0%81.1%-386.7%-
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-369.0%-498.0%-112.9%-560.4%--56.6%---99.5%-

Peer comparison

Same SIC group: Biological Products, (No Diagnostic Substances)

CompanyRevenue (last FY)Net marginROE
TWST---16.4%
AMGN$36.75B21.0%89.1%
RXRX$74.68M-863.4%-57.0%
MRNA$1.94B-145.2%-32.6%
DNA$170.16M-183.8%-61.5%

Comparing Aptose Biosciences Inc. against the 5 most active filers in the same SIC group.